Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a leading genome editing company, today announced that 10 scientific abstracts, including three from research collaborations, have been accepted for presentation at the 21 stAnnual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

The meeting will take place May 16-19 in Chicago. The Company is presenting data on its pipeline and platform technologies to support ongoing development programs.